bioMérieux S.A. (BMXXY) Stock Price & Analysis
bioMérieux S.A. (BMXXY) — price $9.04 (-2.15%), as of the Oct 2, 2026 trading session; market cap $10.7B.
Educational signal · not a buy or sell recommendation · How to read this
bioMérieux S.A. · BMXXY · Healthcare · Medical - Diagnostics & Research
bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $9.04 | |
| Change on the day | -2.15% | |
| 52-week range | $7.12 – $14.62 | |
| Market capitalisation | $10.7B | |
| Price / earnings (trailing) | 19.53 | |
| Shares traded on the day | 100 | |
| Beta (volatility vs the S&P 500) | 0.57 | |
| Dividends per share (last 12 months) | $0.11 | |
| Dividend yield (last 12 months) | 1.25% |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Other perspectives
Council score for bioMérieux (BMXXY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the BMXXY film — every key number, told as a short cinematic story
~2 min · open the film
What is bioMérieux (BMXXY), and what does it report?
Short answer · as of
The business analyzes biological specimens for infectious diseases, cardiovascular conditions and cancers, while also serving quality-control facilities in food, pharmaceuticals, cosmetics and veterinary markets.
Research dated 2026-09-13.
The business analyzes biological specimens for infectious diseases, cardiovascular conditions and cancers, while also serving quality-control facilities in food, pharmaceuticals, cosmetics and veterinary markets. Hospital laboratories, medical practitioners and blood banks therefore sit beside industrial customers in its demand base.
Reported revenue captures a broader activity set than clinical diagnostics alone. The distinguishing feature is the combination of patient testing and manufacturing microbiology, which exposes bioMérieux to laboratory testing volumes as well as quality-control activity across regulated production environments.
What do the latest results show for bioMérieux (BMXXY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $2.20B.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $2.36B Mar 5, 2026
- Latest report · revenue estimate
- $1.11B Mar 5, 2026
- Latest report · revenue vs estimate
- Above estimate Mar 5, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Mar 5, 2026 | $2.36B | $1.11B | $0.2302 | Not available |
| Sep 4, 2025 | $2.41B | $1.32B | $0.1594 | Not available |
| Mar 7, 2025 | $2.15B | $1.24B | $0.1891 | Not available |
| Oct 30, 2024 | $2.04B | $1.04B | $0.1952 | Not available |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $2.20B | $253M | $0.21 (diluted) |
| Q4 FY2025 | $2.25B | $262M | $0.22 (diluted) |
| Q2 FY2025 | $2.29B | $180M | $0.15 (diluted) |
| Q4 FY2024 | $2.32B | $243M | $0.20 (diluted) |
What are the financial strengths and risks for bioMérieux (BMXXY)?
Short answer
The distress and quality screens read Altman Z 6.52 · Piotroski F 9. Trailing ratios: ROE 9.9% · ROA 7.1% · current ratio 2.39 · earnings yield 4.9% · free-cash-flow yield 5.6%.
Common Questions About BMXXY (Healthcare)
Research dated 2026-09-13; the answers below are from that research, and the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does bioMérieux sell to hospital laboratories and industrial control facilities?
bioMérieux provides diagnostic platforms that analyze biological specimens in clinical settings and microbiological tests used for manufacturing quality control. Its customer base therefore extends from hospitals and blood banks to regulated industrial facilities.
Is bioMérieux mainly an infectious-disease testing company?
Infectious-disease detection is central, but the portfolio also addresses cardiovascular conditions, cancers and microbiological quality control. Industrial applications make the company broader than a clinical infectious-disease specialist.
What is the BMXXY stock price today?
The last price recorded on this page for bioMérieux S.A. (BMXXY) is $9.04, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Does BMXXY pay a dividend?
Yes. bioMérieux S.A. (BMXXY) shows a trailing 12-month dividend yield of 1.25%, as of Oct 2, 2026, in the data on this page. Payout ratio and cash-flow coverage decide whether it can last, and past dividends do not guarantee future payments.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (31 figures)
The 31 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 25 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $9.04 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T05:04:36.321Z. | |
px.change | Change on the day | -2.15% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $10.7B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T05:04:34.154Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
id.business_summary | Business description (FMP excerpt) | bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.199 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 19.53 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 100 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.57 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Pierre Boulud | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 15,078 | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | 376 Chemin De l'Orme, Marcy l'Étoile, ARA, 69280, FR | FMP | Financial Modeling Prep (FMP) company profile — The FMP company description names Marcy l'Etoile, France as the headquarters; this page uses the address in this row. | |
fin.q_revenue | Revenue, Q2 FY2026 | $2.20B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
earn.history.depth.2026-03-05.revenue_actual | Revenue · reported — report date 2026-03-05 | $2.36B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.revenue_estimated | Revenue · estimate — report date 2026-03-05 | $1.11B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-05.eps_actual | EPS · reported — report date 2026-03-05 | $0.2302 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-09-04.revenue_actual | Revenue · reported — report date 2025-09-04 | $2.41B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-09-04.revenue_estimated | Revenue · estimate — report date 2025-09-04 | $1.32B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-09-04.eps_actual | EPS · reported — report date 2025-09-04 | $0.1594 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-07.revenue_actual | Revenue · reported — report date 2025-03-07 | $2.15B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-07.revenue_estimated | Revenue · estimate — report date 2025-03-07 | $1.24B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-07.eps_actual | EPS · reported — report date 2025-03-07 | $0.1891 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-30.revenue_actual | Revenue · reported — report date 2024-10-30 | $2.04B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-30.revenue_estimated | Revenue · estimate — report date 2024-10-30 | $1.04B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2024-10-30.eps_actual | EPS · reported — report date 2024-10-30 | $0.1952 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $7.12 – $14.62 | UNRECORDED | Stored company-profile observation — Captured 2026-10-05 | |
fin.scores | Distress and quality screens | Altman Z 6.52 · Piotroski F 9 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 9.9% · ROA 7.1% · current ratio 2.39 · earnings yield 4.9% · free-cash-flow yield 5.6% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
div.ttm_per_share | Dividends per share, last 12 months (split-adjusted) | $0.11 | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history — Sum of 1 split-adjusted declared dividend with an ex-date in the 365 days to 2026-10-04, per current share. Ex-dates are not payment dates; special dividends are included. Not a declared annual rate. | |
div.ttm_yield | Dividend yield, last 12 months | 1.25% | COMPUTED | Financial Modeling Prep (FMP) split-adjusted dividend history and quote — Split-adjusted dividends with ex-dates in the trailing 365-day window divided by the packet price, on the same current-share basis. Price date follows the quote, latest price bar or packet-build day when unstamped. Not a forecast or declared annual rate. | |
earn.history.depth.2026-03-05.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($2.36B) with the recorded estimate ($1.11B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
Fact-family notes
- Earnings-history note. Source series as of 2026-03-05. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-03-05.revenue_actual,earn.history.depth.2026-03-05.revenue_estimated,earn.history.depth.2026-03-05.revenue_actual.comparison,earn.history.depth.2026-03-05.eps_actual,earn.history.depth.2025-09-04.revenue_actual,earn.history.depth.2025-09-04.revenue_estimated,earn.history.depth.2025-09-04.eps_actual,earn.history.depth.2025-03-07.revenue_actual,earn.history.depth.2025-03-07.revenue_estimated,earn.history.depth.2025-03-07.eps_actual,earn.history.depth.2024-10-30.revenue_actual,earn.history.depth.2024-10-30.revenue_estimated,earn.history.depth.2024-10-30.eps_actual.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Sector / industry (provider taxonomy) | Healthcare / Medical - Diagnostics & Research | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | bioMérieux S.A. is a global leader in the development and production of in vitro diagnostic solutions, primarily aimed at detecting infectious diseases. Its operations span the Americas, Europe, the Middle East, Africa, and the Asia Pacific regions. The company provides sophisticated diagnostic platforms that analyze biological specimens to pinpoint infectious diseases, cardiovascular conditions, and various cancers. Additionally, it offers microbiological testing for quality control in manufacturing, serving the food, pharmaceutical, cosmetics, and veterinary industries. Its diverse clientele encompasses clinical and hospital laboratories, medical practitioners, blood banks, and industrial control facilities. Founded in 1963, the company, previously known as B-D Mérieux, maintains its headquarters in Marcy l'Etoile, France. bioMérieux S.A. operates as a subsidiary of Institut Mérieux SA. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.